Remove Drug Research Remove Immune Response Remove Therapies
article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52
article thumbnail

AI in gene delivery vector discovery and design

Drug Target Review

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drug research today. One approach is to look beyond the traditional drug molecule.

article thumbnail

ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development

NIH Director's Blog: Drug Development

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.